Pegylated interferons: chemical and clinical differences

[Guest guest]

Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30.

Pegylated interferons: chemical and clinical differences.

GR.

Professor of Hepatology, Hepatobiliary Group, Adult and Pediatric

Gastroenterology, Institute of Molecular and Cellular Science, Queen 's

School of Medicine and Dentistry, Barts and The Royal London Hospital,

London, UK.

Summary Pegylated interferon therapy for the treatment of chronic hepatitis

C virus provides significant increases in sustained virological response

rates compared with standard interferons. Two pegylated interferons are now

available and are used in conjunction with ribavirin to maximize response

rates in infected patients. The two pegylated interferons,

peginterferonalpha-2a and peginterferonalpha-2b, differ substantially in

terms of their chemical and structural characteristics, pharmacokinetic and

pharmacodynamic properties, and dosing and administration. A full

understanding of the differences between the two drugs is important to

maximize the clinical benefits. Controlled studies designed to characterize

the effects of the two drugs on viral kinetics and sustained virological

response rates are emerging and may help to shed additional light on the use

of these compounds in patients with chronic hepatitis C.

PMID: 15479353 [PubMed - in process]

[Guest guest]

Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30.

Pegylated interferons: chemical and clinical differences.

GR.

Professor of Hepatology, Hepatobiliary Group, Adult and Pediatric

Gastroenterology, Institute of Molecular and Cellular Science, Queen 's

School of Medicine and Dentistry, Barts and The Royal London Hospital,

London, UK.

Summary Pegylated interferon therapy for the treatment of chronic hepatitis

C virus provides significant increases in sustained virological response

rates compared with standard interferons. Two pegylated interferons are now

available and are used in conjunction with ribavirin to maximize response

rates in infected patients. The two pegylated interferons,

peginterferonalpha-2a and peginterferonalpha-2b, differ substantially in

terms of their chemical and structural characteristics, pharmacokinetic and

pharmacodynamic properties, and dosing and administration. A full

understanding of the differences between the two drugs is important to

maximize the clinical benefits. Controlled studies designed to characterize

the effects of the two drugs on viral kinetics and sustained virological

response rates are emerging and may help to shed additional light on the use

of these compounds in patients with chronic hepatitis C.

PMID: 15479353 [PubMed - in process]

[Guest guest]

Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30.

Pegylated interferons: chemical and clinical differences.

GR.

Professor of Hepatology, Hepatobiliary Group, Adult and Pediatric

Gastroenterology, Institute of Molecular and Cellular Science, Queen 's

School of Medicine and Dentistry, Barts and The Royal London Hospital,

London, UK.

Summary Pegylated interferon therapy for the treatment of chronic hepatitis

C virus provides significant increases in sustained virological response

rates compared with standard interferons. Two pegylated interferons are now

available and are used in conjunction with ribavirin to maximize response

rates in infected patients. The two pegylated interferons,

peginterferonalpha-2a and peginterferonalpha-2b, differ substantially in

terms of their chemical and structural characteristics, pharmacokinetic and

pharmacodynamic properties, and dosing and administration. A full

understanding of the differences between the two drugs is important to

maximize the clinical benefits. Controlled studies designed to characterize

the effects of the two drugs on viral kinetics and sustained virological

response rates are emerging and may help to shed additional light on the use

of these compounds in patients with chronic hepatitis C.

PMID: 15479353 [PubMed - in process]

[Guest guest]

Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30.

Pegylated interferons: chemical and clinical differences.

GR.

Professor of Hepatology, Hepatobiliary Group, Adult and Pediatric

Gastroenterology, Institute of Molecular and Cellular Science, Queen 's

School of Medicine and Dentistry, Barts and The Royal London Hospital,

London, UK.

Summary Pegylated interferon therapy for the treatment of chronic hepatitis

C virus provides significant increases in sustained virological response

rates compared with standard interferons. Two pegylated interferons are now

available and are used in conjunction with ribavirin to maximize response

rates in infected patients. The two pegylated interferons,

peginterferonalpha-2a and peginterferonalpha-2b, differ substantially in

terms of their chemical and structural characteristics, pharmacokinetic and

pharmacodynamic properties, and dosing and administration. A full

understanding of the differences between the two drugs is important to

maximize the clinical benefits. Controlled studies designed to characterize

the effects of the two drugs on viral kinetics and sustained virological

response rates are emerging and may help to shed additional light on the use

of these compounds in patients with chronic hepatitis C.

PMID: 15479353 [PubMed - in process]